nach oben

Journal of Endocrinological Investigation

Erschienen in:

20.09.2023 | Brief Report

Gut microbiota, a potential cause of higher insulin sensitivity in children with Prader–Willi syndrome

verfasst von: M.-L. Zhong, Y.-Q. Cai, Y.-F. Tang, Y.-L. Dai, Y.-H. Jiang, Y. Ni, C.-C. Zou

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Obesity is the main driving factor for comorbidities in Prader–Willi syndrome (PWS) patients due to overeating behaviors. The gut microbiota has been implicated in the etiology of obesity and associated comorbidities. The purpose of the present study was to characterize the fecal microbiota in Chinese patients with PWS and compare it to that of patients with obesity as well as healthy controls.

Methods

We conducted a cross-sectional study with 35 PWS patients (PWS), 35 patients with obesity (OB), and 35 healthy controls (HC). Metagenomic sequencing was performed in stool samples.

Results

The composition of the fecal microbiota in PWS patients differed from that of participants in the OB and HC groups. It was characterized by increased Akkermansia Eubacterium, Eubacterium rectale, and Roseburia intestinalis and decreased Parabacteroides and Phascolarctobacterium. Additionally, the homeostatic model assessment of insulin resistance (HOMA-IR) was lower in PWS patients than in patients with obesity. Spearman rank correlation analysis showed that Achromobacter, Acidiphilium, Xylophilus, and Frisingicoccus were significantly negatively correlated with HOMA-IR.

Conclusion

The composition of the gut microbiota in Chinese PWS patients differed from that in patients with obesity, which might contribute to higher insulin sensitivity in PWS patients.

Nur mit Berechtigung zugänglich

Cheon CK (2016) Genetics of Prader-Willi syndrome and Prader-Willi-like syndrome. Ann Pediatr Endocrinol Metab 21(3):126–135. https://doi.org/10.6065/apem.2016.21.3.126CrossRefPubMedPubMedCentral

Butler MG, Hartin SN, Hossain WA, Manzardo AM, Kimonis V, Dykens E, Gold JA, Kim SJ, Weisensel N, Tamura R, Miller JL, Driscoll DJ (2019) Molecular genetic classification in Prader-Willi syndrome: a multisite cohort study. J Med Genet 56(3):149–153. https://doi.org/10.1136/jmedgenet-2018-105301CrossRefPubMed

Bar C, Diene G, Molinas C, Bieth E, Casper C, Tauber M (2017) Early diagnosis and care is achieved but should be improved in infants with Prader-Willi syndrome. Orphanet J Rare Dis 12(1):118. https://doi.org/10.1186/s13023-017-0673-6CrossRefPubMedPubMedCentral

Proffitt J, Osann K, McManus B, Kimonis VE, Heinemann J, Butler MG, Stevenson DA, Gold JA (2019) Contributing factors of mortality in Prader-Willi syndrome. Am J Med Genet A 179(2):196–205. https://doi.org/10.1002/ajmg.a.60688CrossRefPubMed

Pacoricona Alfaro DL, Lemoine P, Ehlinger V, Molinas C, Diene G, Valette M, Pinto G, Coupaye M, Poitou-Bernert C, Thuilleaux D, Arnaud C, Tauber M (2019) Causes of death in Prader-Willi syndrome: lessons from 11 years’ experience of a national reference center. Orphanet J Rare Dis 14(1):238. https://doi.org/10.1186/s13023-019-1214-2CrossRefPubMedPubMedCentral

Qian Y, Xia F, Zuo Y, Zhong M, Yang L, Jiang Y, Zou C (2022) Do patients with Prader-Willi syndrome have favorable glucose metabolism? Orphanet J Rare Dis 17(1):187. https://doi.org/10.1186/s13023-022-02344-3CrossRefPubMedPubMedCentral

Ramon-Krauel M, Amat-Bou M, Serrano M, Martinez-Monseny AF, Lerin C (2021) Targeting the gut microbiome in Prader-Willi syndrome. J Clin Med 10(22):5328. https://doi.org/10.3390/jcm10225328CrossRefPubMedPubMedCentral

Peng Y, Tan Q, Afhami S, Deehan EC, Liang S, Gantz M, Triador L, Madsen KL, Walter J, Tun HM, Haqq AM (2020) The gut microbiota profile in children with Prader-Willi syndrome. Genes (Basel) 11(8):904. https://doi.org/10.3390/genes11080904CrossRefPubMed

Olsson LM, Poitou C, Tremaroli V, Coupaye M, Aron-Wisnewsky J, Bäckhed F, Clément K, Caesar R (2020) Gut microbiota of obese subjects with Prader-Willi syndrome is linked to metabolic health. Gut 69(7):1229–1238. https://doi.org/10.1136/gutjnl-2019-319322CrossRefPubMed

10.

Zhang C, Yin A, Li H, Wang R, Wu G, Shen J, Zhang M, Wang L, Hou Y, Ouyang H, Zhang Y, Zheng Y, Wang J, Lv X, Wang Y, Zhang F, Zeng B, Li W, Yan F, Zhao Y, Pang X, Zhang X, Fu H, Chen F, Zhao N, Hamaker BR, Bridgewater LC, Weinkove D, Clement K, Dore J, Holmes E, Xiao H, Zhao G, Yang S, Bork P, Nicholson JK, Wei H, Tang H, Zhang X, Zhao L (2015) Dietary modulation of gut microbiota contributes to alleviation of both genetic and simple obesity in children. EBioMedicine 2(8):968–984. https://doi.org/10.1016/j.ebiom.2015.07.007CrossRefPubMedPubMedCentral

11.

Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD, Levenez F, Chilloux J, Hoyles L, Dumas ME, Rizkalla SW, Doré J, Cani PD, Clément K (2016) Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65(3):426–436. https://doi.org/10.1136/gutjnl-2014-308778CrossRefPubMed

12.

Mukherjee A, Lordan C, Ross RP, Cotter PD (2020) Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health. Gut Microbes 12(1):1802866. https://doi.org/10.1080/19490976.2020.1802866CrossRefPubMedPubMedCentral

13.

Kuang YS, Lu JH, Li SH, Li JH, Yuan MY, He JR, Chen NN, Xiao WQ, Shen SY, Qiu L, Wu YF, Hu CY, Wu YY, Li WD, Chen QZ, Deng HW, Papasian CJ, Xia HM, Qiu X (2017) Connections between the human gut microbiome and gestational diabetes mellitus. Gigascience 6(8):1–12. https://doi.org/10.1093/gigascience/gix058CrossRefPubMedPubMedCentral

14.

Kreznar JH, Keller MP, Traeger LL, Rabaglia ME, Schueler KL, Stapleton DS, Zhao W, Vivas EI, Yandell BS, Broman AT, Hagenbuch B, Attie AD, Rey FE (2017) Host genotype and gut microbiome modulate insulin secretion and diet-induced metabolic phenotypes. Cell Rep 18(7):1739–1750. https://doi.org/10.1016/j.celrep.2017.01.062CrossRefPubMedPubMedCentral

15.

Karcher N, Pasolli E, Asnicar F, Huang KD, Tett A, Manara S, Armanini F, Bain D, Duncan SH, Louis P, Zolfo M, Manghi P, Valles-Colomer M, Raffaetà R, Rota-Stabelli O, Collado MC, Zeller G, Falush D, Maixner F, Walker AW, Huttenhower C, Segata N (2020) Analysis of 1321 Eubacterium rectale genomes from metagenomes uncovers complex phylogeographic population structure and subspecies functional adaptations. Genome Biol 21(1):138. https://doi.org/10.1186/s13059-020-02042-yCrossRefPubMedPubMedCentral

16.

De Vadder F, Joly A, Leulier F (2021) Microbial and nutritional influence on endocrine control of growth. J Mol Endocrinol 66(3):R67–R73. https://doi.org/10.1530/JME-20-0288CrossRefPubMed

17.

Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF (2017) The microbiota-gut-brain axis in obesity. Lancet Gastroenterol Hepatol 2(10):747–756. https://doi.org/10.1016/S2468-1253(17)30147-4CrossRefPubMed

Titel: Gut microbiota, a potential cause of higher insulin sensitivity in children with Prader–Willi syndrome
verfasst von: M.-L. Zhong
Y.-Q. Cai
Y.-F. Tang
Y.-L. Dai
Y.-H. Jiang
Y. Ni
C.-C. Zou
Publikationsdatum: 20.09.2023
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 4/2024
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-023-02194-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X-linked hypophosphatemic rickets

A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials

Nano Morgante: the most famous buffoon of Cosimo I de’Medici

Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study

Establishing a valid cohort of patients with acromegaly by combining the National Patient Register with the Swedish Pituitary Register

Evaluation of a large set of patients with Autoimmune Polyglandular Syndrome from a single reference centre in context of different classifications